HK Stock Market Move | TYK MEDICINES-B (02410) rose more than 5%, the company completed the full circulation of H shares, and the application for listing of Aducanumab was formally accepted and included in priority review.

TYK MEDICINES-B (02410) rose more than 5%, as of press time, up 4.92% to HK$11.34, with a turnover of HK$27.5877 million. On the news front, on March 4, TYK MEDICINES-B announced that the company's board of directors is pleased to announce that 4.608 million non-listed shares have been converted into H shares on March 4, 2026, and these converted H shares will be listed on the Hong Kong Stock Exchange starting at 9 am on March 5, 2026. Recently, TYK MEDICINES-B announced that its independently developed alectinib mesylate tablets (TY-9591) for the treatment of brain metastasis in non-small cell lung cancer (NSCLC) have officially been accepted for new drug application (NDA) by the National Medical Products Administration (NMPA) Drug Evaluation Center (CDE) in China. This is a new generation EGFR-TKI inhibitor targeting lung cancer brain metastasis. The NDA submission is based on the results of a multicenter, randomized, open-label, positive-controlled pivotal registration clinical study (ESAONA) conducted in China (NCT05948813). The results of this study will be presented at an upcoming international academic conference or journal.